This page helps user to browse peptides present in approved biotech drug category in DrugBank.
| DrugBank ID | Name | Sequence | N-ter Mod | C-ter Mod | Linear/ Cyclic | Chirality | Chemical Modification | Origin | Biological Property | Half- life | Test- Sample |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DB00063 | Eptifibatide | HGDWPC | Mpa (mercaptopropionic acid) | Amidation | Cyclic | L | Homo-arginine, disulphide bond between Mpa and Cys | Derived from a protein found in the venom of the southeastern pygmy rattlesnake | Platelet aggregation inhibitor | 150 minutes | Not mentioned |
| DB00007 | Leuprolide | PHWSYLLR | Pyro glutamic acid | Ethylamide | Linear | L | None | Gonadotropin releasing hormone | Analog of gonadotropin releasing hormone | 3 hours | Intravenous |
| DB06719 | Buserelin | HWSYsLRP | Pyro-Histidine | Ethylamide | Linear | Mix | t-butyl serine 5 | LHRH | Stimulates GnRHR | 50 to 80 minutes | Intravenous |
| DB06719 | Buserelin | HWSYsLRP | Pyro-Histidine | Ethylamide | Linear | Mix | t-butyl serine 5 | LHRH | Stimulates GnRHR | 80 minutes | Subcutaneous |
| DB06719 | Buserelin | HWSYsLRP | Pyro-Histidine | Ethylamide | Linear | Mix | t-butyl serine 5 | LHRH | Stimulates GnRHR | 1 to 2 hours | Intranasal |
| DB00067 | Vasopressin | CYFQNCPRG | Free | Amidation | Linear | L | None | Vassopressin | Antidiuretic hormone | 10 to 20 minutes | Not mentioned |
| DB00107 | Oxytocin | CYIQNCPLG | Free | Amidation | Cyclic (C1-C6) | L | None | Oxytocin | Multiple functions during pregnancy | 1 to 6 minutes | Intravenous |
| DB04985 | PCK3145 | PGDSTRKCMDLKGNK | Free | Free | Linear | L | None | Segment of prostate secretory protein (PSP94) | Treatment of late stage Hormone Refractory Prostate Cancer (HRPC) | 21 to 87 minutess | Not mentioned |
| DB00006 | Bivalirudin | FPRPGGGGNGDFEEIPEEYL | Free | Free | Linear | L | None | Hirudin variant | Thrombin inhibitor | 25 minutes | Intravenous |
| DB01284 | Cosyntropin | SYSMEHFRWGKPVGK KRRPVKVYP | Free | Free | Linear | L | None | N-terminal segment of ACTH | Diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. | 15 minutes | Intravenous (Human) |
| DB04900 | Thymalfasin | SDAAVDTSSEITTKDLK EKKEVVEEAEN | Acetylation | Free | Linear | L | None | Human thymosin alpha 1 | Immunostimulant, treatment of HepatitisB and C | 2 hours | Subcutaneous |
| DB00017 | Salmon Calcitonin | CSNLSTCVLGKLSQELHK LQTYPRTNTGSGTP | Free | Free | Linear | L | None | Calcitonin | Calcium metabolism | 58 minutes | Intramuscular |
| DB00017 | Salmon Calcitonin | CSNLSTCVLGKLSQELHK LQTYPRTNTGSGTP | Free | Free | Linear | L | None | Calcitonin | Calcium metabolism | 59 to 64 minutes | Subcutaneous |
| DB00017 | Salmon Calcitonin | CSNLSTCVLGKLSQELHK LQTYPRTNTGSGTP | Free | Free | Linear | L | None | Calcitonin | Calcium metabolism | 18 to 23 minutes | Nasal |
| DB04899 | Nesiritide | SPKMVQGSGCFGRKMD RISSSSGLGCKVLRRH | Free | Free | Linear | L | None | Recombinant human B-type natriuretic acid | Promotes vasodilation, natriuresis, and diuresis. | 18 minutess | Intravenous (Human) |
| DB06655 | Liraglutide | HAEGTFTSDVSSYLEGQ AAKEEFIIAWLVKGRG | Free | Free | Linear | L | Palmitic acid addition | GLP-1 | GLP-1 receptor agonist | 13 hours | Subcutaneous |
| DB06285 | Teriparatide | SVSEIQLMHNLGKHLNS MERVEWLRKKLQDVHNF | Free | Free | Linear | L | None | Segment of PTH hormone | Treatment of osteoporosis | 1 hour | Subcutaneous |
| DB00109 | Enfuvirtide | YTSLIHSLIEESQNQQEKN EQELLELDKWASLWNWF | Acetylation | Amidation | Linear | L | None | Envelope polyprotein GP160 precursor | Inhibitor of fusion between HIV and CD4 | 3.8 hours | Subcutaneous |
| DB01278 | Pramlintide | KCNTATCATQRLANFLVH SSNNFGPILPPTNVGSNTY | Free | Amidation | Cyclic (C2-C7) | L | None | Pancreatic hormone | Adjunct treatment of diabetes I and II | 48 minutes | Subcutaneous |
| DB01285 | Corticotropin | SYSMEHFRWGKPVGKKR RPVKVYPDGAEDQLAEAFPLEF | Free | Free | Linear | L | None | Pitutary hormone | Diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. | 15 minutes | Intravenous (Human) |
| DB08869 | Tesamorelin | YADAIFTNSYRKVLGQLSA RKLLQDIMSRQQGESNQERGARARL | trans-3-hexenoyl group | Amidation | Linear | L | None | hGRF | Reduces abdominal fat | 26 hours | Subcutaneous (healthy human) |
| DB08869 | Tesamorelin | YADAIFTNSYRKVLGQLSAR KLLQDIMSRQQGESNQERGARARL | trans-3-hexenoyl group | Amidation | Linear | L | None | hGRF | Reduces abdominal fat | 38 hours | Subcutaneous (HIV infected human) |
| DB01307 | Insulin detemir | (Chain A: GIVEQCCTSICSL YQLENYCN)(Chain B: FVNQHLC GSHLVEALYLVCGERGFFYTPK) | Free | Free | Linear | L | Myristic acid bound to lysine-29 in B-chain | Insulin | Glucose metabolism | 5 to 7 hours | Subcutaneous (Human) |
| DB00030 | Insulin regular (chain A)(chain B) | (Chain A: GIVEQCCTSICSL YQLENYCN) (Chain B: FVNQHLC GSHLVEALYLVCGERGFFYTPKT) | Free | Free | Cyclic | L | Disulphide bond between chain A and chain B | Insulin | Glucose metabolism | 4 to 6 minutes | Not mentioned |
| DB00046 | Insulin lispro | (Chain A: GIVEQCCTSICSLY QLENYCN)(Chain B: FVNQHLCGSH LVEALYLVCGERGFFYTKPT) | Free | Free | Cyclic | L | Disulphide bond between chain A and chain B | Insulin | Glucose metabolism | 1 hour | Subcutaneous |
| DB01306 | Insulin aspart | (Chain A: GIVEQCCTSICSLY QLENYCN)(Chain B: FVNQHLCGSH LVEALYLVCGERGFFYTDKT) | Free | Free | Cyclic | L | Disulphide bond between chain A and chain B | Insulin | Glucose metabolism | 81 minutes | Subcutaneous |
| DB01309 | Insulin glulisine | (Chain A: GIVEQCCTSICSLY QLENYCN)(Chain B: FVKQHLCGSH LVEALYLVCGERGFFYTPET) | Free | Free | Cyclic | L | Disulphide bond between chain A and chain B | Insulin | Glucose metabolism | 42 minutes | Subcutaneous |
| DB00047 | Insulin glargine | (Chain A: GIVEQCCTSICSLY QLENYCG)(Chain B: FVNQHLCGSH LVEALYLVCGERGFFYTPKTRR) | Free | Free | Cyclic | L | Disulphide bond between chain A and chain B | Insulin | Glucose metabolism | 30 hours | Human reticulocytes |
| DB00001 | Lepirudin | LVYTDCTESGQNLCLCEGSNV CGQGNKCILGSDGEKNQCVTGEGTP KPQSHNDGDFEEIPEEYLQ | Free | Free | Linear | L | None | Hirudin variant | Treatment of heparin-induced thrombocytopenia | 1.3 hours | Not mentioned |